top of page

Adecto Pharmaceuticals awarded Phase I NCI STTR grant for the development of ADAM8 targeted therapies

BOSTON, Mass. (April 15, 2016) - Adecto Pharmaceuticals, Inc. has been awarded a Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute of the National Institutes of Health. This Phase 1 award will support the development of Adecto Pharma’s antibody-based targeted therapies against ADAM8, a critical driver of tumor growth and metastasis, for the treatment of patients with triple-negative breast cancers. 

Please reload

bottom of page